Tumor Biology

, Volume 32, Issue 1, pp 159–166 | Cite as

Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features

  • Miao-zhen Qiu
  • Bing Han
  • Hui-yan Luo
  • Zhi-wei Zhou
  • Zhi-qiang Wang
  • Feng-hua Wang
  • Yu-hong Li
  • Rui-hua Xu
Research Article


The impact of hypoxia-inducible factor (HIF)-1α and hexokinase-II (HK-II) expression on prognosis of gastric adenocarcinoma patients has not been clearly established. We identified all patients in Cancer Center of Sun Yat-Sen University who were diagnosed as gastric adenocarcinoma and underwent radical gastrectomy between January 1999 and December 2001. We used immunohistochemistry to determine the expressions of HIF-1α protein and HK-II in the surgical sections. We identified 188 patients with gastric adenocarcinoma for the final analysis. The positive rate of HIF-1α and HK-II were 110/188 (54.6%) and 40/188 (21.3%), respectively. Both HIF-1α and HK-II were all positively correlated with tumor size, lower differentiation, and tumor stage. Univariate analysis showed that advanced tumor stages (P < 0.001), tumor size (P = 0.003), HIF-1α expression (P < 0.001), and HK-II expression (P < 0.001) were all significantly associated with shorter survival. The multivariate Cox analysis revealed that tumor stage (P < 0.001), HIF-1α expression (P < 0.001), and HK-II expression (P = 0.002) remained independent prognostic variables for survival. In addition, there was a positive correlation of HIF-1α protein expression and HK-II (P = 0.022). Both HIF-1α and HK-II were overexpressed in gastric adenocarcinoma. The multivariate Cox analysis revealed that both of them were independent factors on survival of gastric adenocarcinoma patients.


HIF-1α HK-II Gastric adenocarcinoma Immunohistochemistry Survival 



These work was funded by National Natural Science Foundation of China grant 30672408, Guangzhou Bureau of Science and Technology grant 2006Z3-E0041 and Sun Yat-Sen University 985 Program Initiation Fund (China). We gratefully thank the staff members in the Department of Medical Oncology and GI Surgery Oncology at Sun Yat-Sen University Cancer Center for their suggestion and assistance.

Part of the results of this article was present in the 2008 ASCO annual meeting as a poster.


  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;10:2137–50.CrossRefGoogle Scholar
  2. 2.
    Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24:68–72.CrossRefPubMedGoogle Scholar
  3. 3.
    Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1998;14:831–8.Google Scholar
  4. 4.
    Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor-1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999;59:3915–8.PubMedGoogle Scholar
  8. 8.
    Elson DA, Ryan HE, Snow JW, Johnson R, Arbeit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes dring multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 2000;60:6189–95.PubMedGoogle Scholar
  9. 9.
    Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, et al. Role of hypoxia-inducible factor 1 alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Sweeney MJ, Ashmore J, Morris HP, Weber G. Comparative biochemistry hepatomas. IV. isotope studies of glucose and fructose metabolism in liver tumors of different growth rate. Cancer Res. 1963;23:995–1002.PubMedGoogle Scholar
  11. 11.
    Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst. 1967;38:839–63.PubMedGoogle Scholar
  12. 12.
    Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett. 1991;291:55–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Adams V, Kempf W, Hassam S, Briner J. Determination of hexokinase isoenzyme I and II composition by RT-PCR: increased hexokinase isoenzyme II in human renal cell carcinoma. Biochem Mol Med. 1995;54:53–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Rempel A, Bannasch P, Mayer D. Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. Biochim Biophys Acta. 1994;1219:660–8.PubMedGoogle Scholar
  15. 15.
    Katabi MM, Chan HL, Karp SE, Batist G. HexokinasetypeII: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gene Ther. 1999;10:155–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem. 1995;270:29083–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 1997;29:339–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Srinivas V, Leshchinsky I, Sang N, King MP, Minchenko A, Caro J. Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J Biol Chem. 2001;276:21995–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol. 2004;40:117–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol. 2007;19:223–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.PubMedGoogle Scholar
  23. 23.
    Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rössler K, Prodinger A, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangigenesis. Cancer. 2001;92:165–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309–14.CrossRefPubMedGoogle Scholar
  25. 25.
    Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Hypoxia-inducible factor 1alpha expression in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res. 2001;7:1661–8.PubMedGoogle Scholar
  26. 26.
    Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, et al. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci. 2005;96:176–82.CrossRefPubMedGoogle Scholar
  27. 27.
    Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911–6.PubMedGoogle Scholar
  28. 28.
    Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–3.PubMedGoogle Scholar
  29. 29.
    Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–16.PubMedGoogle Scholar
  30. 30.
    Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res. 2006;12:5112–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Koukourakis MI, Giatromanolaki A, Skarlatos J, Corti L, Blandamura S, Piazza M, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001;61:1830–2.PubMedGoogle Scholar
  32. 32.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573–81.CrossRefPubMedGoogle Scholar
  33. 33.
    Nakanishi K, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Matsuyama S, et al. Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res. 2005;11:2583–90.CrossRefPubMedGoogle Scholar
  34. 34.
    Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology. 2007;72:111–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277:23111–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002;1555:14–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Rho M, Kim J, Jee CD, Lee YM, Lee HE, Kim MA, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res. 2007;27:251–8.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2010

Authors and Affiliations

  • Miao-zhen Qiu
    • 1
    • 2
  • Bing Han
    • 1
    • 2
  • Hui-yan Luo
    • 1
    • 2
  • Zhi-wei Zhou
    • 1
    • 3
  • Zhi-qiang Wang
    • 1
    • 2
  • Feng-hua Wang
    • 1
    • 2
  • Yu-hong Li
    • 1
    • 2
  • Rui-hua Xu
    • 1
    • 2
  1. 1.State Key Laboratory of Oncology in South ChinaGuangzhouChina
  2. 2.Department of Medical OncologySun Yat-Sen University Cancer CenterGuangzhouChina
  3. 3.Department of GI SurgerySun Yat-Sen University Cancer CenterGuangzhouChina

Personalised recommendations